2022 World Conference on Lung Cancer (ePosters)-EP08.03-006. Survival After Radical Treatment of Oligometastatic Non-small Cell Lung Cancer: A Multicenter Analysis

EP08.03-006. Survival After Radical Treatment of Oligometastatic Non-small Cell Lung Cancer: A Multicenter Analysis

Pdf Summary

A multicenter analysis was conducted to assess the outcomes of local ablative treatment (LAT) in patients with oligometastatic non-small cell lung cancer (NSCLC). The study included patients who underwent surgery of the primary tumor and radical treatment of distant metastases between 2001 and 2021. The results showed that in patients with limited systemic tumor burden, LAT with surgical resection of the primary tumor can be safely performed. The 5-year overall survival (OS) in this selected subgroup of patients exceeded the reported survival rates of stage IV NSCLC.<br /><br />A total of 144 patients with oligometastatic NSCLC were included in the analysis. The majority of patients had adenocarcinoma (77.1%), followed by squamous-cell carcinoma (16%) and other types of carcinoma. The most common metastatic site was the brain, followed by bone and adrenals. The majority of patients presented with metastases in a single organ, and almost half had no nodal metastases.<br /><br />The surgical resection of the primary tumor was successful in the majority of cases, with a high rate of R0 resection achieved. Neoadjuvant systemic treatment was administered in some cases, and immunotherapy and stereotactic body radiation therapy (SBRT) were also used in a subset of patients.<br /><br />The median overall survival after surgery was 33 months, with 1-, 2-, and 5-year OS rates of 76%, 59%, and 40%, respectively. Neoadjuvant systemic treatment showed a trend towards significantly influencing median OS.<br /><br />In conclusion, LAT including surgical resection of the primary tumor can be a safe and effective treatment option for patients with oligometastatic NSCLC and limited systemic tumor burden. These findings suggest that in this selected subgroup of patients, survival rates exceed those reported for stage IV NSCLC.

Asset Subtitle

Isabelle Opitz

Meta Tag

Speaker Isabelle Opitz

Topic Metastatic Non-small Cell Lung Cancer Oligometastatic Disease

Keywords

multicenter analysis

local ablative treatment

LAT

oligometastatic non-small cell lung cancer

NSCLC

surgery

distant metastases

overall survival

adenocarcinoma

squamous-cell carcinoma